Cancer Research

Cancer Research Program

Research Investigators

May Hashimi, M.D. Hematology-Oncology

Interim Director of Cancer Research/Research Nurse

Julie Koch, RN, BSN, OCN, CCRP
Phone: (708) 763-2707
Cell: (708) 238-7574

Research Nurse

Julie Koch, RN, BSN, OCN, CCRP
Phone: (708) 238-7574

Regulatory Affairs

Carrie Hansen
Phone: (708) 763-2719

Active Protocols by Disease Site

Breast

Prevention
Alliance A011401
Breast Cancer Weight-Loss Study (BWEL Study) Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer NCT02750826

• BMI > 27kg/m2 documented within 56 days prior to registration. Most recent BMI must be used for eligibility
• Self-reported ability to walk at least 2 blocks (at any pace)
• Histologically confirmed invasive breast cancer and registration must occur within 14 months after the first diagnosis
• No history of invasive breast cancer in 5 years prior to registration other than the current diagnosis (prior DCIS at any time is acceptable)
• All adjuvant or neoadjuvant chemotherapy, radiation, and surgery completed at least 21 days prior to registration
• All subjects must have sentinel lymph node biopsy and/or axillary lymph node dissection
• Must meet comorbid conditions of the protocol
• ECOG Status 0 or 1

Alliance A011502

Phase II Double-Blinded Placebo-Controlled Trial of Aspirin as Adjuvant Therapy for Node-Positive HER2 Negative Breast Cancer: The ABC Trial NCT02927249

• The patient can be male or female, with any ER/PgR status
• Patient must be enrolled within 18 months of diagnosis if ER/PgR negative or within 10 years if ER/Pgr positive
• ECOG Status 0-2
• No history of GI Bleeding requiring transfusion, stroke, MI, a-fib
• No chronic daily use of steroids or anti-coagulants
• No prior malignancy of any type within the past 5 years other than breast cancer, basal or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix

Adjuvant 

NRG-BR003A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer NCT02488967

• The tumor must be unilateral invasive adenocarcinoma of the breast on histological exam
• Primary tumor must be pT1-3, pN0-3.  If pN0, tumor must be > 3.0cm.
• The tumor must have been determined to be HER2-negative
• The tumor must have been determined to be ER and PgR Negative. Patients with < 1% ER and PgR staining by IHC are considered negative
• Patients must have undergone sentinel lymph node biopsy and/or axillary lymph node dissection

Colon/Rectal

Prevention

SWOG S0820

Stage 0-IIIA Double-Blind Placebo-Controlled Trial of Eflornithine andSuldinac to Prevent Recurrence of High-Risk Adenomas and Stage 0-III Second Primary Colorectal Cancers in Patients with Colon or Rectal Cancer Phase III-Preventing Adenomas of the Colon with PACES NCT01349881

• History of Stage 0, I, II or III colon or rectal cancer within 180-456 days of primary resection
• One year post-op colonoscopy showing no evidence of disease
• ECOG Status 0-1
• Must have a pure tone audiometry evaluation to document air conduction within 30 days prior to registration
• Must not have documented hx of gastric/duodenal ulcer within 12 months